Skip to content

MK-0518 integrase inhibitor effective in treatment-naive patients

Kaletra monotherapy as effective as triple therapy for at least 18 months

Efavirenz more durable than Kaletra over two years in treament-naive patients

Abacavir/3TC backbone proves most durable for children over five years

High rates of TB after beginning ART in Africa — but decreases observed over time

Two-class ART just as good as three-class in the long-term, and has fewer side-effects

Very low CD4, rural care, linked to higher risk of death on ARVs in African studies

Lowered AZT dose for low weight patients 'effective and reduces toxicity'

People with history of depression more likely to stop efavirenz due to mental health problems